Novo Nordisk , whose global profile has risen along with demand for its Wegovy weight-loss drug, is bolstering operations in ...

Danish drug maker Novo Nordisk has struck partnerships with 10 Indian artificial intelligence (AI) startups to streamline its ...

France is the latest European country to refuse to cover weight loss drugs through its national insurance programme.View on ...

Senator Elizabeth Warren told the Federal Trade Commission that the acquisition of contract manufacturer Catalent could ...

Thermo Fisher Scientific is responsible for helping to produce some of the hottest drugs on the market, including Novo ...

The $200B GLP-1 market is set to expand with 16 new obesity drugs launching by 2029, challenging Novo Nordisk and Eli Lilly's dominance while addressing scalability and pricing concerns.

The FDA updated its database of drugs in shortage to remove tirzepatide, which had sat on that list – along with related ...

France has refused to endorse prescribing weight loss drug, Wegovy through its national insurance system, despite being on ...

Novo Nordisk is broadening its Bengaluru operations by increasing senior leadership, doubling global process leaders in India, and boosting headcount by 16% next year. The company is also ...

Novo Nordisk has been slowly increasing production capacity of its highly coveted weight loss drugs. As a result, thousands of people have began treatment per week. Wegovy has been FDA-approved ...

Ozempic, Wegovy, and Eli Lilly And Co's (NYSE:LLY) Mounjaro and Zepbound have fueled an illicit market of counterfeit and ...

As the obesity clinical trials evolve, there is a growing emphasis on how decentralisation and new technologies can play a ...